76
|
Kageyama G, Onishi A, Ueda Y, Kamei Y, Yamada H, Ichise Y, Waki D, Naka I, Tsuda K, Okano T, Takahashi S, Nishida M, Akashi K, Nishimura K, Sendo S, Kogata Y, Saegusa J, Morinobu A. THU0611 Subjective Well-Being of Japanese RA Patients Who Reach Treatment Target Is Higher than The Japanese Average. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
77
|
Inui K, Orita K, Okano T, Mamoto K, Sugioka Y, Tada M, Koike T, Nakamura H. AB0209 Female Sex Increases The Risk of Forefoot Deformity in Patients with Rheumatoid Arthritis:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
78
|
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H. THU0112 Prevalence and Risk Factors for New Vertebral Fractures in Patients with RA: Five-Year Follow-up of The Tomorrow Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
79
|
Anno S, Inui K, Mamoto K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. SAT0135 Achieving Freedom from Glucocorticoids Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of The Tomorrow Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
80
|
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H. AB0376 Retention Rates and Clinical Efficacy of Tocilizumab as First-Line Biologics Compared To Second-Line in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
81
|
Inui K, Koike T, Sugioka Y, Okano T, Mamoto K, Tada M, Nakamura H. THU0098 No Relationship between Low Serum 25-Hydroxyvitamin D Level and Decreased Bone Mass or Bone Quality in Patients with Rheumatoid Arthritis – Tomorrow Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
82
|
Kageyama G, Onishi A, Ueda Y, Kamei Y, Yamada H, Ichise Y, Waki D, Naka I, Tsuda K, Okano T, Takahashi S, Nishida M, Akashi K, Nishimura K, Sendo S, Kogata Y, Saegusa J, Morinobu A. AB0192 Some of The Painful RA Patients Underrate Global Health VAS at Hospitals. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
83
|
Yamada Y, Inui K, Mamoto K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. FRI0105 Low Thoracic Bone Mineral Density and Glucocorticoid Are Risk Factors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of The Tomorrow Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
84
|
Anno S, Inui K, Mamoto K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. SAT0136 Patients with Rheumatoid Arthritis and High Levels of Anti-Cyclic Citrullinated Peptide Antibody under Treatment with High-Dose Glucocorticoid Frequently Fall: Five-Year Findings of The Tomorrow Study: Table 1. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.5226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
85
|
Tada M, Inui K, Okano T, Sugioka Y, Mamoto K, Koike T, Nakamura H. FRI0141 Bone Mineral Density of Whole Body Can Predict Fractures in Patients with Rheumatoid Arthritis: Findings from The Tomorrow Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
86
|
Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T, Nakamura H. Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study. Osteoporos Int 2016; 27:729-35. [PMID: 26294294 DOI: 10.1007/s00198-015-3291-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 08/11/2015] [Indexed: 01/30/2023]
Abstract
UNLABELLED Decreasing the daily dose of glucocorticoids improved bone metabolic marker levels in patients with rheumatoid arthritis. However, changes in disease activity did not influence bone metabolism. Bone metabolism might thus remain uncontrolled even if disease activity is under good control. Decreasing glucocorticoid dosage appears important for improving bone metabolism. INTRODUCTION Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption is increased and bone formation is inhibited in patients with RA, and glucocorticoid negatively affects bone metabolism. We aimed to investigate factors influencing bone metabolic markers in patients with RA. METHODS We started the 10-year prospective cohort Total Management of Risk Factors in Rheumatoid Arthritis Patients to Lower Morbidity and Mortality (TOMORROW) study in 2010. We compared changes in urinary cross-linked N-telopeptide of type I collagen (uNTx) and serum osteocalcin (OC), as markers of bone resorption and formation, respectively, in 202 RA patients and age- and sex-matched volunteers between 2010 and 2011. We also investigated factors influencing ΔuNTx and ΔOC in the RA group using multivariate analysis. RESULTS Values of ΔuNTx were significantly lower in patients with RA than in healthy controls (-0.51 vs. 7.41 nmol bone collagen equivalents (BCE)/mmol creatinine (Cr); p = 0.0013), whereas ΔOC values were significantly higher in RA patients (0.94 vs. 0.37 ng/ml; p = 0.0065). Changes in prednisolone dosage correlated negatively with ΔOC (β = -0.229, p = 0.001), whereas changes in disease activity score, bisphosphonate therapy, and period of biologics therapy did not correlate significantly with ΔOC. No significant correlation was seen between ΔuNTx and change in prednisolone dosage. CONCLUSIONS Decreased glucocorticoid dosage improved bone metabolic markers in RA, but disease activity, bisphosphonate therapy, and period of biologics therapy did not influence levels of bone metabolic markers. Decreasing glucocorticoid dosage appears important for improving bone metabolic marker profiles in patients with RA.
Collapse
|
87
|
Okano T, Seike M, Kuribayashi H, Soeno C, Ishii T, Kida K, Gemma A. Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. Int J Oncol 2016; 48:945-52. [PMID: 26783151 PMCID: PMC4750543 DOI: 10.3892/ijo.2016.3330] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 11/23/2015] [Indexed: 12/14/2022] Open
Abstract
To date, a number of potential biomarkers for lung squamous cell cancer (SCC) have been identified; however, sensitive biomarkers are currently lacking to detect early stage SCC due to low sensitivity and specificity. In the present study, we compared the 7 serum proteomic profiles of 11 SCC patients, 7 chronic obstructive pulmonary disease (COPD) patients and 7 healthy smokers as controls to identify potential serum biomarkers associated with SCC and COPD. Two-dimensional difference gel electrophoresis (2D-DIGE) and mass-spectrometric analysis (MS) using an affinity column revealed two candidate proteins, haptoglobin (HP) and apolipoprotein 4, as biomarkers of SCC, and α-1-antichymotrypsin as a marker of COPD. The iTRAQ technique was also used to identify SCC-specific peptides. HP protein expression was significantly higher in SCC patients than in COPD patients. Furthermore, two HP protein peptides showed significantly higher serum levels in SCC patients than in COPD patients. We established novel polyclonal antibodies for the two HP peptides and subsequently a sandwich enzyme-linked immunosorbent assay (ELISA) for the quantification of these specific peptides in patient and control sera. The sensitivity of detection by ELISA of one HP peptide (HP216) was 70% of SCC patients, 40% of COPDs patients and 13% of healthy controls. We also measured CYFRA, a cytokeratin fragment clinically used as an SCC tumor marker, in all the 28 cases and found CYFRA was detected in only seven SCC cases. However, when the measurement of HP216 was combined with that of CYFRA, 100% (10 of 10 patients) of SCC cases were detected. Our proteomic profiling demonstrates that the SCC-specific HP peptide HP216 may potentially be used as a diagnostic biomarker for SCC.
Collapse
|
88
|
Ito K, Saiki H, Sakaguchi T, Hayashi K, Nishii Y, Watanabe F, Hataji O, Okano T, Naito M, Ibata H, Fujiwara A, Yoshida M, Itani H, Tanigawa M, Kobayashi H. 457P Background of patients (pts) with ALK rearranged (ALK+) non-small-cell lung cancer (NSCLC), and efficacy and safety of ALK inhibitors (ALK-Is) in actual clinical practice: Multicenter retrospective study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv532.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
89
|
Kubo H, Shioyama T, Oura M, Suzuki A, Ogawa T, Makino H, Takeda S, Kino-oka M, Shimizu T, Okano T, Yamamori S. Development of automated 3-dimensional tissue fabrication system Tissue Factory - Automated cell isolation from tissue for regenerative medicine. ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE 2015; 2013:358-61. [PMID: 24109698 DOI: 10.1109/embc.2013.6609511] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We have developed a new automated cell isolation system as one of the modules of automated cell sheet production system named Tissue-Factory (T-Factory). This system enables isolation of the target cells from tissue. Using this new system, we successfully isolated skeletal myoblast from skeletal muscle tissue. The cell isolation system makes us stably prepare cell suspension from each tissue automatically and safely. Isolation of skeletal myoblasts will contribute to labor-saving cell cultivation and operational stability, and lead further process in tissue engineering and regenerative medicine.
Collapse
|
90
|
Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T, Nakamura H. FRI0062 Influence of Biologic Agents on Bone Mineral Density and Bone Mineral Markers in Patients with Rheumatoid Arthritis: Data from the Airtight Study: Table 1. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
91
|
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H. FRI0137 Medication Interval of Adalimumab for Rheumatoid Arthritis Patients Might be Extended After the Achievement of Low Disease Activity -Kabuki Study-. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2609] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
92
|
Mamoto K, Inui K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. FRI0084 High Levels of Anti-Cyclic Citrullinated Peptide Antibodies and High Doses of Glucocorticoid are Risk Factors for Falls in Patients with Rheumatoid Arthritis: Fourth-Year Results of the Tomorrow Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
93
|
Anno S, Inui K, Mamoto K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. AB0481 Abatacept Might not Alter Anti-Cyclic Citrullinated Peptide Levels in Established Rheumatoid Arthritis Patients -Airtight Study-. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
94
|
Anno S, Inui K, Mamoto K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. THU0368 Work Ability and Work Disability Evaluation in Patients with Rheumatoid Arthritis – from the Tomorrow Study: Table 1. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
95
|
Mamoto K, Inui K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. SAT0077 Ultrasonography as a Potent Tool for Predicting Radiographic Progression in Rheumatoid Arthritis Treated with Biological Agents. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
96
|
Inui K, Koike T, Tada M, Sugioka Y, Mamoto K, Okano T, Nakamura H. AB0359 Sarcopenia is Apparent in Patients with Rheumatoid Arthritis, Especially Those Treated with Biologics -Tomorrow Study-. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
97
|
Okano T, Filippucci E, Draghessi A, Di Carlo M, Carotti M, Salaffi F, Wright G, Grassi W. SAT0593 Ultrasonographic Evaluation of Joint Damage in Knee Osteoarthritis: A Comparison with Conventional Radiography. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
98
|
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H. OP0219 Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Even After Achieving Clinical Remission Might Reduce the Radiological Joint Damage -Scrum Study-. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
99
|
Yamaguchi O, Kawashima A, Shiono A, Maeno Y, Ishikawa R, Masumoto A, Utsugi H, Daito H, Okano T, Murayama Y, Kobayashi K. [Hange-Shashin-to for preventing diarrhea during afatinib therapy]. Gan To Kagaku Ryoho 2015; 42:581-583. [PMID: 25981651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Afatinib is an epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI). In a randomized phase III study(Lux- Lung 3 study)employing patients harboring EGFR mutations, patients administered afatinib show a significantly longer progression free survival time(PFS)than those administeredcombination chemotherapy comprising cisplatin andpemetrexed . However, most of the patients(95.2%)treatedwith afatinib experiencedd iarrhea. In the present report, 16 patients with EGFR mutations were treatedby afatinib at our institution from May 2014 to December 2014. Twelve patients were administered a diarrhea prevention herbal medicine, Hange-shashin-to. Seven of 12 patients(58%)had no diarrhea during the 28 days of therapy. All 4 of the patients who did not receive Hange-shashin-to experienced diarrhea above Grade 1 within 6 days of starting therapy. The rate of diarrhea differed significantly between the patients receiving and not receiving Hangeshashin- to. In conclusion, preventive administration of Hange-shashin-to may reduce the occurrence of diarrhea during afatinib treatment.
Collapse
|
100
|
Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Nishii Y. A novel synthetic vitamin D3 analogue, 2-beta-(3-hydroxypropoxy)-calcitriol (ED-71): its biological activities and pharmacological effects on calcium metabolism. CONTRIBUTIONS TO NEPHROLOGY 2015; 91:116-22. [PMID: 1800002 DOI: 10.1159/000420166] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A novel vitamin D3 analogue, [2 beta-(3-hydroxypropoxy)-calcitriol: ED-71] showed a similar Ca-regulating activity as calcitriol in the in vivo and in vitro Ca mobilization test and ex vivo intestinal Ca absorption assay using vitamin D-deficient rats. The differentiation-inducing activity of ED-71 in mouse myeloid leukemia cell line (WEHI-3 cell) was slightly less than that of calcitriol. ED-71 distributes predominantly in plasma as an intact form and its half-life plasma was twice as long as that of calcitriol. Further study revealed that the higher binding potency of ED-71 to plasma-specific vitamin D-binding protein (DBP) compared with that of calcitriol accounts for its stability in the blood circulation. The pharmacological effect of ED-71 for the animal models with osteoporosis seemed to be better than that calcitriol. These results suggest that ED-71 should become a valuable therapeutic long-acting drug for patients with osteoporosis.
Collapse
|